RxDoctor Payments Data

Allan Kurtz, DO

Internal Medicine · Woodland Hills, CANPI 1679656946

Payments from drug & device makers

$13,070in general payments, 2019–2025

Across 721 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$1K
  • AstraZeneca$998
  • Merck$722
  • GSK$631
  • Pfizer$587
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$12,91799%
  • Education$1531%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)137$2,276
Amgen(2 entities)95$1,328
AstraZeneca47$998
Merck38$722
GSK33$631
Pfizer38$587
Boehringer Ingelheim25$546
Johnson & Johnson30$523
Teva Pharmaceuticals USA, Inc.20$461
Novo Nordisk28$421
Amarin Pharma, Inc.22$418
Takeda Pharmaceuticals U.S.A., Inc.19$384
Lilly USA, LLC18$356
Astellas Pharma US Inc11$303
Novartis13$285
Kowa Pharmaceuticals America, Inc.16$270
Abbott9$204
Sanofi-aventis U.S. LLC11$189
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)6$173
Eisai Inc.8$148
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC8$128
Bayer5$119
Nestle Healthcare Nutrition Inc.5$99
Idorsia Pharmaceuticals US Inc4$76
Esperion Therapeutics, Inc.3$63
Forte Bio-pharma LLC1$61
Almatica Pharma LLC3$59
Upsher-smith Laboratories LLC4$58
Biohaven Pharmaceutical Holding Company Ltd.3$57
Radius Health, Inc.3$56
Lundbeck LLC4$56
Exact Sciences3$52
Biohaven Pharmaceuticals, Inc.3$52
Tolmar, Inc.3$51
Vertex2$50
Vertiflex, Inc.3$48
Dexcom, Inc.3$46
Alkermes, Inc.2$41
Assertio Therapeutics, Inc.2$39
Lucid Diagnostics Inc.2$38
Abiomed1$35
Endo Pharmaceuticals Inc.2$35
Avion Pharmaceuticals2$34
Ionis Pharmaceuticals, Inc.1$32
Arbor Pharmaceuticals, Inc.2$30
Biofire Diagnostics, LLC2$27
Viiv Healthcare Company1$25
Otsuka America Pharmaceutical, Inc.1$24
Heartflow, Inc.1$22
Gilead1$22
Linus Health, Inc.1$22
Bausch Health US, LLC1$22
Biogen1$21
Embecta Corp.1$20
Dynasplint Systems Inc.1$20
ARS Pharmaceuticals Operations, Inc.1$20
Clarus Therapeutics Inc.1$20
Shield Therapeutics Inc1$20
Xeris Pharmaceuticals, Inc.1$19
Sumitomo Pharma America, Inc.1$18

How this compares

$13,070 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$639,362
Medicare patients
761
Services billed
37,410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban166$157,573
JardianceEmpagliflozin132$117,742
RybelsusSemaglutide103$109,979
OzempicSemaglutide97$99,279
Trelegy ElliptaFluticasone/Umeclidin/Vilanter93$82,091
FarxigaDapagliflozin Propanediol73$70,632
XareltoRivaroxaban55$64,358
JanuviaSitagliptin Phosphate54$60,504
MounjaroTirzepatide39$39,798
WegovySemaglutide24$33,291
Repatha SureclickEvolocumab37$32,272
TradjentaLinagliptin31$30,017
LinzessLinaclotide21$22,043
MyrbetriqMirabegron30$21,668
KeppraLevetiracetam15$20,491

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic, Wegovy$421$242,549224 claims
PfizerEliquis$587$157,573166 claims
Boehringer IngelheimJardiance, Tradjenta$546$147,760163 claims
GSKTrelegy Ellipta, Breo Ellipta$631$100,882125 claims
AstraZenecaFarxiga, Breztri Aerosphere$998$78,88884 claims
MerckJanuvia, Janumet$722$67,98666 claims
Johnson & JohnsonXarelto$523$64,35855 claims
Lilly USA, LLCMounjaro$356$39,79839 claims
AbbVieLinzess, Synthroid$2,276$28,048126 claims
Astellas Pharma US IncMyrbetriq$303$21,66830 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$189$8,76512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Woodland Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →